Antiverse
Antiverse

Antiverse

Measured by StartupHub.aiAgent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Measured by Google PageSpeedSpeed68Site Speed: 68/100. Above median. Measured by Google PageSpeed. Median 62.Measured by StartupHub.aiTrust54Data Trust: 54/100. Below median. Measured by StartupHub.ai. Median 61.

AI-powered antibody discovery platform.

2018Active28London, United Kingdom

About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules

About

Antiverse is a biotechnology company that utilizes artificial intelligence to accelerate antibody discovery and development. Their platform aims to significantly reduce the time and cost associated with bringing new antibody-based therapeutics to market.

Key facts

Website
antiverse.com
Headquarters
London, England, United Kingdom
Founded
2018
Employees
28
Total funding
$16M (Series A)
Business model
B2B

Funding rounds

Funding rounds raised by Antiverse
DateRoundAmountLead investors
3 Mar 2026Series A$9M
15 Oct 2024Seed$5M
15 Mar 2021Seed$2M

Antiverse scores 50. Does yours?

That is its Agent Readiness: how well ChatGPT, Claude and the other agents can read and use a site. Paste your website and you get yours in about a minute.

Add first review

Frequently asked

Is Antiverse trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Antiverse is 54 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Antiverse raised?

Antiverse has raised a total of $16M in funding. The most recent round on record is Series A.

How many employees does Antiverse have?

Antiverse has approximately 28 people on record.

Public record

SEC filings, insider activity, nonprofit links and pay benchmarks for Antiverse